Company
Headquarters: Golden Valley, MN, United States
Employees: 485
CEO: Mr. Timothy P. Herbert
$2.73 Billion
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Abbott | $216.15 B |
| Boston Scientific Corporation | $140.40 B |
| Stryker | $133.15 B |
| Medtronic | $123.20 B |
| Edwards Lifesciences Corporation | $50.10 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and Europe. It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire Medical Systems, Inc. was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | $882.6 M |
| EBITDA | $76.6 M |
| Gross Profit TTM | $749.5 M |
| Profit Margin | 5.05% |
| Operating Margin | 4.30% |
| Quarterly Revenue Growth | 10.50% |
Inspire Medical Systems, Inc. has the following listings and related stock indices.
Stock: NYSE: INSP
Stock: FSX: 2DR